|
||||||||||||||||||||||||||||||||||||||||||||||
|
Multiple Sclerosis Info
Favorite Links
This Month
Month Archive
|
Thursday, September 18
Teva to Present New Treatment Data
by
All About MS
on Thu 18 Sep 2008 11:10 AM CST
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA | Quote | Chart | News | PowerRating) today announced presentations of several new studies at the World Congress on Treatment and Research in Multiple Sclerosis in Montreal. New data will be more »
Friday, April 11
MS Therapies - Copaxone
by
All About MS
on Fri 11 Apr 2008 01:51 PM CST
Glatiramer acetate is used in the treatment of the relapsing-remitting form of multiple sclerosis (MS). This medicine will not cure MS, but may extend the time between relapses.
This medicine is available only with your more »
Monday, March 17
Copaxone preferred by doctors
by
All About MS
on Mon 17 Mar 2008 01:00 AM CST
According to the new report entitled Treatment Algorithms in Multiple Sclerosis, neurologists note that Copaxone's better short-term and long-term side-effect/safety profile, together with its lower rate of induction of neutralizing antibodies, are critical reasons for choosing Copaxone more »
Tuesday, February 26
study - Copaxone - reduced the risk of developing clinically definite MS
by
All About MS
on Tue 26 Feb 2008 07:33 AM CST
The results showed that treatment with COPAXONE® (glatiramer acetate injection) reduced the risk of developing clinically definite MS (CDMS) by 44 percent versus placebo, and more »
Sunday, February 10
Long-term (up to 22 years), study of glatiramer acetate (Copaxone) in relapsing remitting multiple sclerosis.
by
All About MS
on Sun 10 Feb 2008 12:00 AM CST
To evaluate the safety and efficacy of long-term glatiramer acetate (GA) therapy, 46 patients with relapsing remitting multiple sclerosis (RRMS) were treated for up to 22 years in an ongoing, open-label more »
Sunday, January 6
Glatiramer acetate (Copaxone), found to reverse paralysis in mice
by
All About MS
on Sun 06 Jan 2008 12:00 AM CST
Glatiramer acetate (Copaxone), found to reverse paralysis in mice
Monday, December 31
Copaxone - long term use safe
by
All About MS
on Mon 31 Dec 2007 09:31 AM CST
Long-term Use of Glatiramer Acetate (Copaxone) for Multiple Sclerosis Appears Safe and Efficacious: Presented at ECTRIMS By Bruce Sylvester THESSALONIKI, GREECE – September 30, 2005 – Patients with relapsing-remitting multiple ... more »
Wednesday, December 12
Glatiramer Acetate (Copaxone) Injections Reduced Relapses by 75%
by
All About MS
on Wed 12 Dec 2007 08:07 PM CST
Glatiramer Acetate Injections Reduced Relapses by 75% in Both Treatment-Naïve Multiple Sclerosis Patients and Those Failing Interferon Beta-1bMore than 80% of All Patients Experienced an ... more »
Join Shared Solutions with Copaxone
by
All About MS
on Wed 12 Dec 2007 08:04 PM CST
Join Shared Solutions® Become a Member in Canada Shared Solutions® is a free comprehensive multiple sclerosis (MS) patient support program. When you ... more » Wednesday, November 21
Study shows that Copaxone patients walk unaided after 10 years
by
All About MS
on Wed 21 Nov 2007 11:16 AM CST
Data from a 10- year long-term study showed that 92 percent of relapsing-remitting multiple sclerosis (RRMS) patients in the study who remained on COPAXONE(R) (glatiramer acetate injection) were still walking without assistance despite an average disease duration of more than 15 years. These results were published in the more »
Tuesday, August 7
Glatiramer acetate (Copaxone), found to reverse paralysis in mice
by
All About MS
on Tue 07 Aug 2007 10:00 AM CST
UCSF News Office
Wednesday, March 29
Treatment with Glatiramer Acetate Linked to Greater Disease Stability
by
All About MS
on Wed 29 Mar 2006 03:00 AM CST
Patients with early-onset multiple sclerosis have increased disease stability and fewer rates of disease progression when they are treated with glatiramer acetate (Copaxone), according to findings presented here 15th meeting of the European Neurological Society (ENS).
"The results confirm the benefit seen in more »
|
|||||||||||||||||||||||||||||||||||||||||||||
